Clinical Use of Laboratory Tests for the Identification of Secondary Forms of Arterial Hypertension

2007 ◽  
Vol 44 (1) ◽  
pp. 1-85 ◽  
Author(s):  
Gian Paolo Rossi ◽  
Teresa M. Seccia ◽  
Achille C. Pessina
Keyword(s):  
Arterial Hypertension ◽  
Laboratory Tests ◽  
Clinical Use

Critical limb ischaemia in diabetes: definition, assessment, prognosis

VASA ◽  
2001 ◽  
Vol 30 (Supplement 58) ◽  
pp. 21-27
Author(s):  
Luther
Keyword(s):  
Diabetic Foot ◽  
Laboratory Tests ◽  
Critical Limb Ischaemia ◽  
Limb Ischaemia ◽  
Clinical Use ◽  
Arterial Reconstruction ◽  
Arterial Circulation ◽  
Diabetic Foot Disease ◽  
Foot Disease ◽  
Fontaine Classification

In diabetic foot disease, critical limb ischaemia (CLI) cannot be precisely described using established definitions. For clinical use, the Fontaine classification complemented with any objective verification of a reduced arterial circulation is sufficient for decision making. For scientific purposes, objective measurement criteria should be reported. Assessment of CLI should rely on the physical examination of the limb arteries, complemented by laboratory tests like the shape of the PVR curve at ankle or toe levels, and arteriography. The prognosis of CLI in diabetic foot disease depends on the success of arterial reconstruction. The best prognosis for the patients is with a preserved limb. Reconstructive surgery is the best choice for the majority of patients.

scholarly journals Current Drugs with Potential for Treatment of COVID-19: A Literature Review

2020 ◽  
Vol 23 (1) ◽  
pp. 58-64 ◽  
Author(s):  
Md Insiat Islam Rabby
Keyword(s):  
Clinical Trial ◽  
Severe Acute Respiratory Syndrome ◽  
Laboratory Tests ◽  
Literature Search ◽  
Treatment Process ◽  
Clinical Use ◽  
Animal Trial ◽  
Chinese Drugs ◽  
Inflammatory Drugs ◽  
Traditional Chinese Drugs

Purpose: SARS-CoV-2 first emerged in China in December 2019 and rapidly spread worldwide. No vaccine or approved drug is available to eradicate the virus, however, some drugs that are indicated for other afflictions seems to be potentially beneficial to treat the infection albeit without unequivocal evidence.   The aim of this article is to review the published background on the effectiveness of these drugs against COVID-19 Methods: A thorough literature search was conducted on recently published studies which have published between January 1 to March 25, 2020. PubMed, Google Scholar and Science Direct databases were searched Results: A total 22 articles were found eligible. 8 discuss about treatment outcomes from their applied drugs during treatment of COVID-19 patients, 4 report laboratory tests, one report animal trial and other 9 articles discuss recommendations and suggestions based on the treatment process and clinical outcomes of other diseases such as malaria, ebola, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The data and/or recommendations are categorized in 4 classes: (a) anti-viral and anti-inflammatory drugs, (b) anti-malaria drugs, (c) traditional Chinese drugs and (d) other treatments/drugs. Conclusion: All examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trial to be suitable for clinical use.

scholarly journals Epidemiology of Arterial Hypertension in Russian Federation – Importance of Choice of Criteria of Diagnosis

Kardiologiia ◽  
2019 ◽  
Vol 59 (6) ◽  
pp. 5-11 ◽  
Author(s):  
A. M. Erina ◽  
O. P. Rotar ◽  
V. N. Solntsev ◽  
S. A. Shalnova ◽  
A. D. Deev ◽  
...  
Keyword(s):  
Arterial Hypertension ◽  
Russian Federation ◽  
American Heart Association ◽  
Laboratory Tests ◽  
American Heart ◽  
Heart Association ◽  
Russian Population ◽  
Cvd Risk ◽  
Gender And Age ◽  
European Society Of Cardiology

Purpose. Assessment of prevalence of arterial hypertension (AH), need for prescription of antihypertensive therapy (AHT), and efficacy of AHT in Russian population in accordance with novel guideline of the American College of Cardiology/American Heart Association (“American recommendations”) on diagnosis and treatment of AH (2017).Materials and methods. Epidemiological study ESSE-RF (ЭССЕ-РФ) was carried out in 12 regions of Russian Federation (RF) with different climatic-geographic characteristics. Number of examined residents of RF aged 25–65 years was 20 652. The sample was stratified by  gender and age. Examination included anthropometry, laboratory tests, blood pressure (BP) measurement with the OMRON tonometer. The SCORE scale was used for evaluation of risk of development of cardiovascular diseases (CVD). In  American recommendations AH was defined as  follows: 1-st degree  – systolic BP (SBP) 130–139  and/or diastolic BP (DBP) 80–89 mm Hg, 2-nd degree – BP ≥140/90 mm Hg and/or presence of AHT. In recommendations of the European Society of Cardiology (2013, 2018) (“European recommendations”) AH was defined as BP ≥140/90 mm Hg and/or presence of AHT.Results. We analyzed data of examination of  20 607  participants – 7806 men (37.9%) and 12 801  women (62.1%). According to  European recommendations AH was diagnosed in 10 347  persons (50.2%)  – 3987 men (51.1%) men and 6 360 women (49.7%). According to American recommendations AH was registered in 14 853 persons (72.1%) – 6 059 men (77.6%) and 8 794 women (68.7%). AHT received 6324 persons (61.1% of those with AH); according to American recommendations, the onset of AHT was indicated to additional 620 persons with 1-st degree AH because of high CVD risk. Among all participants with AH (on and without AHT) strengthening of AHT for achievement of target BP level was required in 77.8 and 92.6% of patients according to European and American recommendations, respectively.Conclusion. Application of novel criteria of AH diagnosis from 2017 ACC/AHA guideline to Russian population would increase prevalence of AH up to 72.1%. Onset of AHT would be indicated in 13.8% of patients with 1-st degree AH, while in 93% of patients receiving AHT its strengthening would be required. 

Gene therapy targeting FVIII, FIX for haemophilia treatment

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Gene Therapy ◽  
Laboratory Tests ◽  
Laboratory Research ◽  
Pharmaceutical Companies ◽  
Pharmacological Properties ◽  
Clinical Use ◽  
Laboratory Studies ◽  
Regulatory Bodies ◽  
Ongoing Monitoring

Treatment for haemophilia is shifting away from standard factor replacement therapy and toward genetic repair or rebalancing, as well as overall haemostasis equilibrium. Some of these newer drugs may not have specific testing available to determine their haemostasis effects. The effects of gene therapy FVIII or FIX in vivo are under investigation, and it is expected to vary between people; nonetheless, ongoing monitoring of FVIII or FIX activity will be required. The rapid regulatory approval and adoption of emicizumab into routine clinical use surprised many haemostasis labs. Because of the challenges of monitoring patients on emicizumab, laboratories with expertise in designing alternative tests are most suited to do so.Future drugs with similar pharmacological properties to current treatments will not have a similar influence on laboratory tests. Before putting new pharmaceuticals into clinical use, pharmaceutical companies must do extensive laboratory research, and regulatory bodies must ensure that adequate laboratory studies have been completed and are available in the literature.

Clinical use of drugs monitoring via laboratory tests: pilot study in a General Hospital: GRP024 Table 1

2012 ◽  
Vol 19 (2) ◽  
pp. 93.3-94
Author(s):  
A. Cabello ◽  
C. Iniesta ◽  
E. Urbieta ◽  
C. Garcia-Molina ◽  
L. Rentero ◽  
...  
Keyword(s):  
Pilot Study ◽  
General Hospital ◽  
Laboratory Tests ◽  
Clinical Use

scholarly journals Once again about the clinical efficacy and safety of sartans

2014 ◽  
Vol 11 (4) ◽  
pp. 84-86
Author(s):  
Ye S Minina ◽  
B R Khadzhieva
Keyword(s):  
Angiotensin Ii ◽  
Arterial Hypertension ◽  
Clinical Efficacy ◽  
Angiotensin Receptor Blockers ◽  
Clinical Use ◽  
Angiotensin Receptor ◽  
Efficacy And Safety ◽  
Receptor Blockers

Sartans are safety and effective class of anti-hypertensives nowadays. Sartans are the most effective inpatients suffering from arterial hypertension. Their efficiency is determined by the association of Angiotensin II type 1 receptor. Candesartan and azilsartan are themost powerful and approved angiotensin receptor blockers. Candesartan in comparison with azilsartan has wide proposed spectrum of clinical use. Azilsartan is indicated for the treatment of arterial hypertension. In terms of efficiency and safety we showed these sartans.

Sign in / Sign up

Export Citation Format

Share Document